PubRank

J Isola

Author PubWeight™ 138.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995 6.60
2 Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994 5.52
3 Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998 4.22
4 Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997 4.02
5 Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005 4.00
6 Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997 3.37
7 Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001 3.31
8 Aggressiveness of screen-detected breast cancers. Lancet 1995 3.07
9 Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996 2.83
10 Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A 1998 2.80
11 Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000 2.41
12 A digital atlas of breast histopathology: an application of web based virtual microscopy. J Clin Pathol 2004 2.40
13 Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer 2000 2.24
14 Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992 2.10
15 Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000 2.07
16 Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997 2.03
17 Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000 2.01
18 Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res 1996 1.89
19 Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999 1.82
20 Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol 2006 1.68
21 Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol 2007 1.64
22 Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001 1.60
23 Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization. Genes Chromosomes Cancer 1997 1.59
24 Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol 1999 1.42
25 Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res 1995 1.38
26 Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992 1.36
27 Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 1997 1.34
28 Effect of age on the survival of breast cancer patients. Eur J Cancer 1997 1.30
29 Virtual microscopy. J Clin Pathol 2004 1.24
30 Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol 2002 1.22
31 Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 1996 1.17
32 MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res 2000 1.16
33 Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. Br J Cancer 2001 1.15
34 Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1996 1.13
35 Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 1998 1.13
36 Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet Cell Genet 1999 1.12
37 HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 2004 1.12
38 Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol 1997 1.10
39 HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001 1.07
40 Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization. Genes Chromosomes Cancer 1999 1.07
41 p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol 2007 1.06
42 Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 2005 1.03
43 Colocalization of peptide and glucocorticoid receptor immunoreactivities in rat central amygdaloid nucleus. Neuroendocrinology 1992 1.03
44 Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol 2000 1.02
45 Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry 1991 1.02
46 Molecular cytogenetics of human breast cancer. Cold Spring Harb Symp Quant Biol 1994 1.02
47 Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 1994 1.01
48 Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma. Int J Cancer 2000 1.01
49 A regression model for identifying patients at high risk of hypotension, bradycardia and nausea during spinal anesthesia. Acta Anaesthesiol Scand 1992 1.00
50 Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer 1995 0.99
51 Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy. Br J Cancer 1995 0.98
52 Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol 1997 0.98
53 Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Am J Pathol 1993 0.98
54 Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res 2001 0.95
55 HER2 oncogene amplification in extramammary Paget's disease. Histopathology 2003 0.95
56 Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol 1992 0.94
57 Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. Neuropathol Appl Neurobiol 2006 0.94
58 Mapping the amplification of EIF3S3 in breast and prostate cancer. Genes Chromosomes Cancer 2000 0.93
59 Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol 1994 0.93
60 Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization. Cancer Res 1996 0.92
61 A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals. J Clin Pathol 2007 0.92
62 Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. Cancer Causes Control 2010 0.91
63 A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer. J Clin Pathol 2008 0.91
64 Gluten affects epithelial differentiation-associated genes in small intestinal mucosa of coeliac patients. Clin Exp Immunol 2007 0.91
65 Analysis of p53 tumor suppressor gene in families with multiple glioma patients. J Neurooncol 2001 0.90
66 The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography. Breast Cancer Res Treat 2001 0.89
67 Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 1995 0.89
68 New prognostic factors in prostatic carcinoma. Eur Urol 1993 0.89
69 Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas. Am J Pathol 1997 0.88
70 Mechanical loading regulates tenascin-C expression in the osteotendinous junction. J Cell Sci 1999 0.88
71 The visibility of cancer on earlier mammograms in a population-based screening programme. Eur J Cancer 1999 0.88
72 Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol 2011 0.87
73 Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 1997 0.86
74 5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines. Genes Chromosomes Cancer 2001 0.85
75 Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology 2002 0.85
76 High topoisomerase IIalpha expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol 2000 0.83
77 Localization of the glucocorticoid receptor in testis and accessory sexual organs of male rat. Mol Cell Endocrinol 1993 0.82
78 Incidence of atherosclerosis in the internal mammary artery. Ann Thorac Surg 1989 0.81
79 Immunocytochemical localization of progesterone receptor in the chick ovary. Endocrinology 1987 0.81
80 Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer. Anticancer Res 2002 0.81
81 c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br J Cancer 1996 0.81
82 Genetic aberrations in pediatric acute lymphoblastic leukemia by comparative genomic hybridization. Cancer Genet Cytogenet 1997 0.81
83 Hormone replacement therapy and biological aggressiveness of breast cancer. Lancet 1997 0.81
84 Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma. Br J Cancer 1990 0.81
85 Direct eye visualization of Cy5 fluorescence for immunocytochemistry and in situ hybridization. J Histochem Cytochem 2000 0.81
86 Ultrarapid Ki-67 immunostaining in frozen section interpretation of gliomas. J Clin Pathol 2005 0.80
87 The visibility of cancer on previous mammograms in retrospective review. Clin Radiol 2001 0.80
88 Effect of radiotherapy on the interpretation of routine follow-up mammography after conservative breast surgery: a randomized study. Br J Cancer 1998 0.80
89 Development of progestin-specific response in the chicken oviduct. Int J Dev Biol 1989 0.80
90 P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J Urol 1997 0.80
91 Immunochemical characterization of a novel mitochondrially located protein encoded by a nuclear gene within the DFNB8/10 critical region on 21q22.3. Biochem Biophys Res Commun 1997 0.80
92 Colocalization of fos- and glucocorticoid receptor-like immunoreactivities in the rat amygdaloid complex after immobilization stress. J Neuroendocrinol 1992 0.80
93 Prognostic variables in predicting pregnancy. A prospective follow up study of 907 couples with an infertility problem. Hum Reprod 1994 0.79
94 Morphology and histochemistry of the myotendineal junction of the rat calf muscles. Histochemical, immunohistochemical and electron-microscopic study. Acta Anat (Basel) 1991 0.79
95 Progesterone receptor in the chick bursa of fabricius: characterization and immunohistochemical localization. Endocrinology 1985 0.79
96 Sources of variation in the assessment of cell proliferation using proliferating cell nuclear antigen immunohistochemistry. Anal Quant Cytol Histol 1994 0.79
97 Evaluation of camera requirements for comparative genomic hybridization. Cytometry 1996 0.78
98 Atrophy and regeneration of rat calf muscles cause reversible changes in the number of nucleolar organizer regions. Evidence that also in nonproliferating cells the number of NORs is a marker of protein synthesis activity. Lab Invest 1993 0.77
99 CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J Neurooncol 1999 0.77
100 No GIST-type c-kit gain of function mutations in neuroblastic tumours. J Clin Pathol 2005 0.77
101 High cell proliferation activity determined by DNA flow cytometry predicts poor prognosis after relapse in prostate cancer. Eur J Cancer 1994 0.77
102 Nuclear origin of progesterone receptor of the chick oviduct cytosol. An immunoelectron microscopic study. Histochemistry 1986 0.77
103 Macromolecular composition of the myotendinous junction. Exp Mol Pathol 1991 0.75
104 Ultrastructure and collagen composition of the myo-fascial junction in rat calf muscles. Acta Anat (Basel) 1992 0.75
105 [Determination of steroid receptors in breast cancer by immunohisto- chemical technics]. Duodecim 1988 0.75
106 Four-color CGH: a new method for quality control of comparative genomic hybridization. Genes Chromosomes Cancer 1999 0.75
107 Monoclonal-antibody-based noncompetitive avidin-biotin assay for lutropin in urine. Clin Chem 1988 0.75
108 Immunoelectron microscopic localization of progesterone receptor in the chick oviduct. J Steroid Biochem 1987 0.75
109 Oestrogen receptor content and cancer cell/stroma ratio in mammary carcinoma. APMIS 1988 0.75
110 Simultaneous localization of calcitonin gene-related peptide and neurotensin in rat central amygdaloid nucleus. Neurosci Lett 1990 0.75
111 Accumulation of p53 protein correlates with tumour proliferative activity in EBV positive Burkitt's lymphoma. Hematol Oncol 1993 0.75
112 Validity of radiological examinations of patients with breast cancer in different age groups in a population based study. Breast 2001 0.75
113 [New studies on breast cancer to predict disease outcome and clinical use of these new tests]. Duodecim 1991 0.75
114 Augmentation of progesterone receptor concentration by progesterone and estrogen treatments in the chick oviduct. J Steroid Biochem 1984 0.75
115 Immunohistochemical versus biochemical estrogen-receptor and progesterone-receptor analysis: correlation with histological parameters. J Cancer Res Clin Oncol 1989 0.75